The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease

Bibliography

• Brady RO, Murray GJ, Moore DF, Schiffmann R. Enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2001;24(Suppl 2):18-24
   PubMed Web of Science ®Google Scholar
• Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA 2000;284:2771-5
   PubMed Web of Science ®Google Scholar
• Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42
   PubMed Web of Science ®Google Scholar
• Desnick RJ, Ioannou YA, Eng CM. Eighth edition. Alfa-galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet al, Sly WS, Valle D, editors, The metabolic & molecular basis of inherited disease. New York: McGraw-Hill, 2001. p. 3733-74
   Google Scholar
• Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006;95:86-92
   PubMedGoogle Scholar
• Hegemann S, Hajioff D, Conti G, et al. Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006;36:654-62
   PubMed Web of Science ®Google Scholar
• Hajioff D, Hegemann S, Conti G, et al. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006;36:663-7
   PubMed Web of Science ®Google Scholar
• Palla A, Hegemann S, Widmer U, Straumann D. Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol 2007;254:1433-42
   PubMed Web of Science ®Google Scholar
• Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153-8
   PubMed Web of Science ®Google Scholar
• Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35
   PubMed Web of Science ®Google Scholar
• Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005;96:842-6
   PubMed Web of Science ®Google Scholar
• Kampmann C, Wiethoff CM, Perrot A, et al. The heart in Anderson Fabry disease. Z Kardiol 2002;91:786-95
   PubMedGoogle Scholar
• Schwarting A, Dehout F, Feriozzi S, et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006;66:77-84
   PubMed Web of Science ®Google Scholar
• Dehout F, Schwarting A, Beck M, et al. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data. Acta Paediatr Suppl 2003;92:14-5
   PubMedGoogle Scholar
• MacDermot KD, Holmes A, Miners AH. Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60
   PubMed Web of Science ®Google Scholar
• Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002;61:249-55
   PubMed Web of Science ®Google Scholar
• Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course. Medicine 2002;81:122-38
   PubMed Web of Science ®Google Scholar
• Warnock DG, West ML. Diagnosis and management of kidney involvement in Fabry disease. Adv Chronic Kidney Dis 2006;13:138-47
   PubMed Web of Science ®Google Scholar
• Sodi A, Ioannidis AS, Mehta A, et al. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol 2007;91:210-4
   PubMed Web of Science ®Google Scholar
• MacDermot KD, Holmes A, Miners AH. Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75
   PubMed Web of Science ®Google Scholar
• Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-27
   PubMed Web of Science ®Google Scholar
• Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson–Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11
   PubMed Web of Science ®Google Scholar
• Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int 2003;64:801-7
   PubMed Web of Science ®Google Scholar
• MacDermot KD, Holmes A, Miners AH. Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75
   PubMed Web of Science ®Google Scholar
• Deegan PB, Baehner AF, Barba Romero MA, et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006;43:347-52
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-28
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54
   PubMed Web of Science ®Google Scholar
• Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40
   PubMed Web of Science ®Google Scholar
• Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-48
   PubMed Web of Science ®Google Scholar
• Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 2007;9:504-9
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16
   PubMed Web of Science ®Google Scholar
• Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003;13:305-13
   PubMed Web of Science ®Google Scholar
• Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of α-galactosidase a infusions for treatment of Fabry disease. Genet Med 2003;5:144-53
   PubMed Web of Science ®Google Scholar
• Wanner C. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies. Int J Clin Pract 2007;61:1234-5
   PubMedGoogle Scholar
• Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2007;2:e598. Published online 11 July 2007, doi:10.1371/journal.pone.0000598
   PubMed Web of Science ®Google Scholar
• Sakuraba H, Murata-Ohsawa M, Kawashima I, et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2006;51:180-8
   PubMed Web of Science ®Google Scholar
• Lidove O, Joly D, Barbey F, et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007;61:293-302
   PubMed Web of Science ®Google Scholar
• Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008;94:319-25
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Murray GJ, Treco D, et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-70
   PubMed Web of Science ®Google Scholar
• Beck M. Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs 2002;11:851-8
   PubMed Web of Science ®Google Scholar
• Ries M, Clarke JT, Whybra C, et al. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J Clin Pharmacol 2007;47:1222-30
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74
   PubMed Web of Science ®Google Scholar
• Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933-46
   PubMed Web of Science ®Google Scholar
• Thurberg BL, Randolph BH, Granter SR, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004;122:900-8
   PubMed Web of Science ®Google Scholar
• Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 2005;84:261-8
   PubMed Web of Science ®Google Scholar
• Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007;30:68-78
   PubMed Web of Science ®Google Scholar
• Murray GJ, Anver MR, Kennedy MA, et al. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 2007;90:307-12
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21:345-54
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007;18:1576-83
   PubMed Web of Science ®Google Scholar
• Pastores GM, Boyd E, Crandall K, et al. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007;22:1920-5
   PubMed Web of Science ®Google Scholar
• Mignani R, Feriozzi S, Pisani A, et al. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 2008;23(5):1628-35
   PubMed Web of Science ®Google Scholar
• Mignani R, Cagnoli L. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications. J Nephrol 2004;17:354-63
   PubMed Web of Science ®Google Scholar
• Baehner F, Kampmann C, Whybra C, et al. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a Phase IIIB study. J Inherit Metab Dis 2003;26:617-27
   PubMed Web of Science ®Google Scholar
• Dehout F, Roland D, Treille de GS, et al. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease. J Inherit Metab Dis 2004;27:499-505
   PubMed Web of Science ®Google Scholar
• Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-44
   PubMed Web of Science ®Google Scholar
• Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118:924-32
   PubMed Web of Science ®Google Scholar
• Hajioff D, Goodwin S, Quiney R, et al. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 2003;92:28-30
   PubMedGoogle Scholar
• Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-94
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007;5:1447-53
   PubMed Web of Science ®Google Scholar
• Jardim L, Vedolin L, Schwartz IV, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 2004;27:229-40
   PubMed Web of Science ®Google Scholar
• Jardim LB, Aesse F, Vedolin LM, et al. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr 2006;64:711-7
   PubMed Web of Science ®Google Scholar
• Jardim LB, Gomes I, Netto CB, et al. Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2006;29:653-9
   PubMed Web of Science ®Google Scholar
• Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007;96:122-7
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Hauer P, Freeman B, et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006;34:53-6
   PubMed Web of Science ®Google Scholar
• Kleinert J, Dehout F, Schwarting A, et al. Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey. Kidney Int 2005;67:1955-60
   PubMed Web of Science ®Google Scholar
• Orteu CH, Jansen T, Lidove O, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 2007;157:331-7
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr Suppl 2007;96:84-6
   PubMedGoogle Scholar
• Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy – a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007;23:535-42
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Garcia de LA, Mehta A, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005;42:247-52
   PubMed Web of Science ®Google Scholar
• Whybra C, Kampmann C, Krummenauer F, et al. The mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307
   PubMed Web of Science ®Google Scholar
• Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-27
   PubMed Web of Science ®Google Scholar
• Beck M, Sunder-Plassman G, Mehta A, et al. Positive results from 3 years of enzyme replacement therapy with agalsidase-alfa in Fabry disease: data from FOS – the Fabry Outcome Study [abstract]. J Inherit Metab Dis 2005;28:164
   Google Scholar
• West M, Nicholls K, Mehta A, et al. Clinical trial summary of agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009 In Press
   Google Scholar
• Feriozzi S, Schwarting A, Sunder-Plassmann G, et al. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2008;29:353-61
   PubMedGoogle Scholar
• Basic-Jukic N, Coric M, Kes P, et al. Anderson–Fabry disease in kidneys from deceased donor. Am J Transplant 2007;7:2829-33
   PubMed Web of Science ®Google Scholar
• Basic-Jukic N, Kes P, Mokos I, Coric M. Do we need more intensive enzyme replacement therapy for Anderson–Fabry disease? Med Hypotheses 2009;72:476-7
   PubMed Web of Science ®Google Scholar
• Mougenot P, Lidove O, Caillaud C, et al. Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women: in reference to pharmacovigilance. Eur J Clin Pharmacol 2008;64:635-9
   PubMed Web of Science ®Google Scholar
• Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with α galactosidase a. Heart 2006;92:357-60
   PubMed Web of Science ®Google Scholar
• Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002;2:4
   PubMed Web of Science ®Google Scholar
• Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-31
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-10
   PubMed Web of Science ®Google Scholar
• Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Pediatrics 2005;115:e344-55
   PubMed Web of Science ®Google Scholar
• Wendt S, Whybra C, Kampmann C, et al. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 2005;28:787-8
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Hollak CE, Donker-Koopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589-95
   PubMed Web of Science ®Google Scholar
• Mehta A, Beck M, Kampmann C, et al. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab 2008;95:114-5
   PubMed Web of Science ®Google Scholar
• Benichou B, Goyal S, Sung C, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 2009;96:4-12
   PubMed Web of Science ®Google Scholar